News
- Author:
- Jim Kling
Publish date: July 5, 2023
Preventative treatment could reduce chronification, but has the potential to worsen comorbidities.
News
- Author:
- Jim Kling
Publish date: July 5, 2023
Intervention also reduced prodromal symptoms in patients who could reliably predict oncoming headaches.
News
- Author:
- Jim Kling
Publish date: June 30, 2023
Real-world analysis suggests potential for improvements in medication overuse and dependency.
News
- Author:
- Jim Kling
Publish date: June 23, 2023
New studies of remote electrical neuromodulation show efficacy in adolescents and safety during pregnancy.
Article
- Author:
- Jim Kling
Publish date: June 22, 2023
First RCT in migraine suggests THC/CBD mix might be best, and that recreational doses may be higher than necessary.
News
- Author:
- Jim Kling
Publish date: June 21, 2023
Groupings somewhat reflect expert consensus, but also suggest therapeutic avenues.
News
- Author:
- Jim Kling
Publish date: June 14, 2023
Study finds similar progression-free and overall survival in 7-day-on/7-day-off schedule, with fewer side effects than 14 days on, 7 days off.
News
- Author:
- Jim Kling
Publish date: June 13, 2023
Results could broaden eligibility for treatment with the antibody-drug conjugate trastuzumab deruxtecan.
News
- Author:
- Jim Kling
Publish date: June 7, 2023
New study challenges the need for using CDK4/6 inhibitors as first line treatment, according to author.
News
- Author:
- Jim Kling
Publish date: June 7, 2023
“We did two systematic reviews to look at the continuing professional development of family physicians in adolescent health, and it turned out that...
News
- Author:
- Jim Kling
Publish date: June 6, 2023
Lower-dose therapy granted PFS and OS gains, with fewer side effects, compared with standard chemotherapy options.
News
- Author:
- Jim Kling
Publish date: June 5, 2023
A novel therapy has a favorable safety profile, and more like it may be on the way.
News
- Author:
- Jim Kling
Publish date: June 4, 2023
The antibody targets delta-like ligand 3, which is one of few surface markers for small cell lung cancer.
News
- Author:
- Jim Kling
Publish date: June 4, 2023
‘Practice-changing’ results could reduce long-term survivor effects among qualifying patients.
News
- Author:
- Jim Kling
Publish date: June 2, 2023
The results of the new study are “encouraging,” but plenty of unanswered questions remain.
